Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$234.38 USD

234.38
566,922

+5.27 (2.30%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $234.35 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks News

Sriparna Ghosal headshot

Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On

The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.

Sreyoshi Mukherjee headshot

Bleak Outlook for Medical Dental Supplies Industry

Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.

LabCorp's (LH) Q4 Earnings Beat Estimates, Margins Rise

LabCorp (LH) registered year-over-year growth in operating segments in Q4.

Ares Management (ARES) Q4 Earnings and Revenues Beat Estimates

Ares Management (ARES) delivered earnings and revenue surprises of 34.00% and 14.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More

Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.

LabCorp (LH) Rides on Solid Diagnostics Despite PAMA Issues

LabCorp's (LH) Covance Drug Development delivers organic growth despite foreign currency headwind.

What's in the Offing for LabCorp's (LH) Earnings in Q4?

With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.

LabCorp (LH) Reports Next Week: Wall Street Expects Earnings Growth

LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp Hits New 52-Week High: What's Driving the Stock?

LabCorp (LH) is optimistic about maintaining its growth momentum on several recent developments.

Urmimala Biswas headshot

LabCorp (LH) Grows on Solid Diagnostics Arm Despite PAMA Headwinds

LabCorp's (LH) Diagnostics business flourishes organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act (PAMA).

QIAGEN Expands Existing Deal With LabCorp for Better Treatment

QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.

LabCorp (LH) Q3 Earnings Surpass Estimates, Tapers View

LabCorp (LH) impresses investors with third-quarter 2019 results on the robust performance of the Covance Drug Development segment.

LabCorp (LH) Tops Q3 Earnings and Revenue Estimates

LabCorp (LH) delivered earnings and revenue surprises of 2.11% and 0.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Medical Products' Oct 24 Earnings Roster: BAX, CERN & More

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

What's in the Offing for LabCorp's (LH) Earnings in Q3?

LabCorp (LH) is expected to have advanced its companion diagnostics and oncology capabilities in the third quarter.

LabCorp (LH) Reports Next Week: Wall Street Expects Earnings Growth

LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sreyoshi Mukherjee headshot

Dental Supplies Industry's Near-Term Outlook Looks Bright

With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.

LabCorp (LH) Names Two Leaders for Major Business Wings

Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.

LabCorp to Expand Hematology Suite With Sysmex America Deal

LabCorp (LH) will get to use Sysmex' advanced XN-9100 system, which is a scalable, modular automation system.

LabCorp's Covance Launches Laboratory Data Management Service

LabCorp (LH) expands service portfolio through Covance's data management portal.

LabCorp (LH) Down 3.4% Since Last Earnings Report: Can It Rebound?

LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Can Value Investors Pick Laboratory Corporation (LH) Stock?

Let's see if Laboratory Corporation (LH) stock is a good choice for value-oriented investors right now from multiple angles.

LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall

While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.

LabCorp (LH) Tops Q2 Earnings Estimates

LabCorp (LH) delivered earnings and revenue surprises of 1.03% and -0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products' Earnings Roster for Jul 25: SYK, BAX & More

Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.